NCT06623409View on ClinicalTrials.gov

Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

November 12, 2024

Primary Completion Date

November 20, 2026

Study Completion Date

November 20, 2026

Conditions
Healthy
Interventions
BIOLOGICAL

GARDASIL®9 (G9)

Suspension administered via intramuscular (IM) injection

BIOLOGICAL

V540B

Experimental vaccine and adjuvant administered via IM injection

Trial Locations (5)

33009

Velocity Clinical Research, Hallandale Beach ( Site 0003), Hallandale

33024

Research Centers of America ( Hollywood ) ( Site 0001), Hollywood

68134

Velocity Clinical Research, Omaha ( Site 0005), Omaha

91206

California Clinical Trials Medical Group managed by PAREXEL ( Site 0008), Glendale

92801

Anaheim Clinical Trials ( Site 0002), Anaheim

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06623409 - Safety and Immunogenicity of V540B in Healthy Adults (V540B-002). | Biotech Hunter | Biotech Hunter